These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 1719688)

  • 21. Survival time and period of catheterization in patients treated with percutaneous nephrostomy for urinary obstruction due to malignancy.
    Radecka E; Magnusson M; Magnusson A
    Acta Radiol; 2006 Apr; 47(3):328-31. PubMed ID: 16613316
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Endoscopic ureteroneocystostomy: palliative urinary diversion in advanced prostatic cancer.
    Chefchaouni MC; Flam TA; Pacha K; Thiounn N; Zerbib M; Debré B
    Tech Urol; 1998 Mar; 4(1):46-50. PubMed ID: 9568777
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Percutaneous urinary diversion in patients with hormone-refractory prostate cancer.
    Dowling RA; Carrasco CH; Babaian RJ
    Urology; 1991 Feb; 37(2):89-91. PubMed ID: 1992595
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinical application of fluoroscopic guided percutaneous antegrade ureteral stents placement for the treatment of malignant ureteral obstruction.
    Liu Y; Wu K; Lai H; Zeng Z; Zhang B
    J Xray Sci Technol; 2019; 27(3):453-460. PubMed ID: 30909269
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Factors Affecting Survival Outcome After Percutaneous Nephrostomy as Palliative Urinary Diversion in Obstructive Uropathy due to Advance Cervical Cancer Patients.
    Noegroho BS; Kurniawan AP; Wijayanti Z; Mustafa A
    Asian Pac J Cancer Prev; 2021 Apr; 22(4):1211-1216. PubMed ID: 33906314
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Long-Term Outcomes of Double-Layered Polytetrafluoroethylene Membrane-Covered Self-Expandable Segmental Metallic Stents (Uventa) in Patients with Chronic Ureteral Obstructions: Is It Really Safe?
    Kim M; Hong B; Park HK
    J Endourol; 2016 Dec; 30(12):1339-1346. PubMed ID: 27736158
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Palliation of obstructive nephropathy due to malignancy.
    Harrington KJ; Pandha HS; Kelly SA; Lambert HE; Jackson JE; Waxman J
    Br J Urol; 1995 Jul; 76(1):101-7. PubMed ID: 7544201
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Long-term follow-up results and complications in cancer patients with persistent nephrostomy due to malignant ureteral obstruction.
    Alma E; Ercil H; Vuruskan E; Altunkol A; Unal U; Gurlen G; Goren V; Gurbuz ZG
    Support Care Cancer; 2020 Nov; 28(11):5581-5588. PubMed ID: 32757161
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Outcome of Palliative Urinary Diversion and Observation for Malignant Extrinsic Ureteral Obstruction.
    Tatenuma T; Tsutsumi S; Yasui M; Noguchi G; Umemoto S; Kishida T
    J Palliat Med; 2020 Feb; 23(2):254-258. PubMed ID: 31834827
    [No Abstract]   [Full Text] [Related]  

  • 30. Percutaneous nephrostomy versus indwelling ureteral stent in the management of gynecological malignancies.
    Song Y; Fei X; Song Y
    Int J Gynecol Cancer; 2012 May; 22(4):697-702. PubMed ID: 22315095
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Subcutaneous urinary diversion: an alternative to percutaneous nephrostomy.
    Lingam K; Paterson PJ; Lingam MK; Buckley JF; Forrester A
    J Urol; 1994 Jul; 152(1):70-2. PubMed ID: 8201692
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Wire-reinforced ureteral stents to rescue from nephrostomy tube in extrinsic ureteral obstruction.
    Dauw CA; Faerber GJ; Hollingsworth JM; Wolf JS
    Can J Urol; 2015 Jun; 22(3):7806-10. PubMed ID: 26068630
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cutaneous ureterostomy as palliative diversion in adults with malignancy.
    MacGregor PS; Montie JE; Straffon RA
    Urology; 1987 Jul; 30(1):31-4. PubMed ID: 2440171
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Results of ureterocystoneostomy for inner urinary diversion in locally advanced prostate carcinoma].
    Wawroschek F; Hamm M; Rathert P
    Urologe A; 1998 Jul; 37(4):372-6. PubMed ID: 9738288
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Percutaneous urinary drainage and ureteric stenting in malignant disease.
    Allen DJ; Longhorn SE; Philp T; Smith RD; Choong S
    Clin Oncol (R Coll Radiol); 2010 Nov; 22(9):733-9. PubMed ID: 20728326
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The value of antegrade stenting for lower ureteric obstruction.
    Jenkins CN; Marcus AJ
    J R Soc Med; 1995 Aug; 88(8):446-9. PubMed ID: 7562827
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Ureteral obstruction associated with prostate cancer: the outcome after ultrasonographic percutaneous nephrostomy.
    Bordinazzo R; Benecchi L; Cazzaniga A; Vercesi A; Privitera O
    Arch Ital Urol Androl; 1994 Sep; 66(4 Suppl):101-6. PubMed ID: 7889041
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The role of percutaneous nephrostomy in malignant urinary tract obstruction.
    Watkinson AF; A'Hern RP; Jones A; King DM; Moskovic EC
    Clin Radiol; 1993 Jan; 47(1):32-5. PubMed ID: 8428414
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Indications for percutaneous nephrostomy in patients with obstructive uropathy due to malignant urogenital neoplasias.
    Romero FR; Broglio M; Pires SR; Roca RF; Guibu IA; Perez MD
    Int Braz J Urol; 2005; 31(2):117-24. PubMed ID: 15877830
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Management of benign ureteral strictures following radical cystectomy and urinary diversion for bladder cancer.
    Tal R; Sivan B; Kedar D; Baniel J
    J Urol; 2007 Aug; 178(2):538-42. PubMed ID: 17570422
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.